Benzinga · Mar 10, 2026
CL
NASDAQ · CLRB
Cellectar Biosciences, Inc.
Healthcare · Biotechnology
$2.48
Up+$0.12 (+4.84%)
Updated Aug 14, 2026, 6:24 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 12.1M
- P/E ratio
- -0.21
- Dividend yield
- 0.00%
- 52-week range
- $2.20 – $6.52
- Volume
- 30.39K
- Avg. volume
- 156.38K
Price performance
CLRB price history
1M range · 0 trading sessions · Daily adjusted prices
CLRB does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest CLRB news
The latest Smart Investors Daily articles mentioning CLRB.
Stock researchCompany · Overview
CLRB research
Overview
Company profile and research snapshot.
Company profile
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $12.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 10, 2026 | Maxim Group | Buy | — |
| May 14, 2025 | Maxim Group | Hold | — |
| Dec 11, 2024 | Oppenheimer | Perform | — |
| Nov 19, 2024 | Oppenheimer | Outperform | — |
| Oct 11, 2024 | Oppenheimer | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 10, 2026
Maxim Group Upgrades Cellectar Biosciences to Buy, Announces $10 Price Target
Maxim Group analyst Jason McCarthy upgrades Cellectar Biosciences (NASDAQ:CLRB) from Hold to Buy and announces $10 price target.
SeekingAlpha · Mar 4, 2026
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Benzinga · Mar 4, 2026
Cellectar Biosciences Q4 EPS $(0.53) Beats $(2.29) Estimate
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(2.29) by 76.89 percent. This is a 76.67 percent decrease over losses of $(0.30) per share
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
